Abstract
Pre-exposure oral prophylaxis with antiviral drugs is a potential method for preventing transmission of human immunodeficiency virus type 1 (HIV-1). We show that oral delivery of CMPD167, a small molecule that binds to the CCR5 coreceptor, for 10–14 d can protect a substantial proportion of macaques from vaginal infection with a CCR5-using virus (SHIV-162P3). The macaques that became infected despite receiving CMPD167 had reduced plasma viremia levels during the earliest stages of infection.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: predicting HIV transmission & resistance
Scientific Reports Open Access 07 December 2011
-
Clinical use of CCR5 inhibitors in HIV and beyond
Journal of Translational Medicine Open Access 27 January 2011
Access options
Subscribe to Journal
Get full journal access for 1 year
$79.00
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.

References
Youle, M. & Wainberg, M.A. AIDS 17, 937–938 (2003).
Shattock, R.J. & Moore, J.P. Nat. Rev. Microbiol. 1, 25–34 (2003).
AIDS Vaccine Advocacy Coalition. Will a pill a day prevent HIV? Anticipating the results of the tenofovir “PREP” trials. A special publication of the AIDS Vaccine Advocacy Coalition (AVAC). http://www.avac.org/pdf/tenofovir.pdf. (2005).
Seibert, C. & Sakmar, T.P. Curr. Pharm. Des. 10, 2041–2062 (2004).
Barber, C.G. Curr. Opin. Investig. Drugs 5, 851–861 (2004).
Watson, C., Jenkinson, S., Kazmierski, W. & Kenakin, T.P. Mol. Pharmacol. 67, 1268–1282 (2005).
Kuhmann, S.E. et al. J. Virol. 78, 2790–2807 (2004).
Veazey, R.S. & Lackner, A.A. Nat. Med. 11, 469–470 (2005).
Veazey, R.S. et al. Nature, published online 30 October 2005 (10.1038/nature04055).
Veazey, R.S. et al. J. Exp. Med. 198, 1551–1562 (2003).
Wolinsky, S.M. et al. Virology 328, 19–29 (2004).
Tsai, C.C. et al. Science 270, 1197–1199 (1995).
Tsai, C.C. et al. J. Virol. 72, 4265–4273 (1998).
Marx, P.A. et al. Nat. Med. 2, 1084–1089 (1996).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Martin S. Springer is an employee of Merck Inc., but this company did not fund the study.
Rights and permissions
About this article
Cite this article
Veazey, R., Springer, M., Marx, P. et al. Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med 11, 1293–1294 (2005). https://doi.org/10.1038/nm1321
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1321
This article is cited by
-
Oral Administration of the CCR5 Inhibitor, Maraviroc, Blocks HIV Ex Vivo Infection of Langerhans Cells within the Epithelium
Journal of Investigative Dermatology (2013)
-
Clinical use of CCR5 inhibitors in HIV and beyond
Journal of Translational Medicine (2011)
-
Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: predicting HIV transmission & resistance
Scientific Reports (2011)
-
Preexposure Prophylaxis for HIV Prevention
Current HIV/AIDS Reports (2011)
-
Pharmacologic Opportunities for HIV Prevention
Clinical Pharmacology & Therapeutics (2010)